Get started

Coronavirus (COVID-19)

EUR/USD !!!critical levels to watch!!!Hello everyone, The pair is trading around a very critical support levels: 1- On the daily chart (left picture): on the verge of breaking the 50 SMA for the first time since May. 2- Tested the uptrend line from below which is a typical bearish behavior upon breakout. 3- On the 4H chart (right picture): Broke below 200 and 240 SMA for the first time since May. 4- Getting close to breaking the uptrend support line that's been holding since August. Watch out for the above levels, do not trade before a confirmation of breakout and be aware of false breakouts. Good luck, have a nice trading week.
by RamziAbouAbdallah-CMT
MRNA HOLD BULLISHI am not swinging this one, even though it is tempting. I recently sold NVAX at 15% profit, and due to strong correlation with MRNA I was considering selling my MRNA as well, in which case I would have made 14% right now. However, I decided to hold because of 2 reasons : 1) AstraZeneca just took a major hit (if you don't know about it, catch up on the news). This takes out a bit of competition and investor fund distribution might come this way 2) MRNA shows a strong uptrend with good momentum, and that is mainly why I will HOLD it for longer term. Hit like if you found this helpful and interesting. Thanks, E
NASDAQ:MRNA
by BlockTechEv
9
Is MRNA revealing major upside opportunity? BULL or BEAR? Today we're looking at MRNA aka Moderna, the darling biotech that might be the savior of us all should they produce an mRNA vaccine that could be more easily produced and distributed at scale than a traditional vaccine candidate. Reading into this story I've been intrigued, especially with the nice patterns forming in this chart with an easy to identify Impulse wave and a correction pattern currently forming. Unfortunately, this is always the riskier proposition and we must consider our Bull and Bear cases objectively so that we have a plan. As you'll see, we recently bounced off the 0.5 fib retracement from the all-time high of $95 all the way back to $53. Looks like a healthy bounce off that level. But we should almost always expect it. There is nothing to get excited about until we see a more convincing bounce with volume. While I love the long term pattern being set up in this chart with that hopeful bull target of $136.99, there's a lot of work to make up and resistance to overcome before we get anywhere close. The declining volume is something to watch out for. If you zoom in you'll see the upward channel off the bounce paired with the declining volume. This would indicate that short term we'll retest the low, and if we're lucky we can get a buying opportunity off that low and off the 0.618 at $43.50. Set your ladders appropriately and always calculate your stop loss according to risk preference fo % loss below average calculated cost. If you plan your buy levels and amount in advance you can easily calculate the average buy price and then subtract 20% for example to reach a reasonable stop loss which shields you from setting a stop loss too high and missing the following run, or setting it too low and losing more than you are willing to. Meanwhile, looking at the long term trend, we'll have some trading potential on the stock, but need to look for some volatility within the current correction pattern. Given the sharp increase and resulting decrease, one can assume we might see similar moves again in the future, though there's nothing to indicate exactly when at the moment until we see a better channel or a convincing wedge reveal itself. The longer-term trend bodes well for your everyday investor who's willing to take some loss for a very large potential gain. Should Moderna create their mRNA based vaccine in time and be successful with distribution, the value of this company would quickly skyrocket. I'm willing to bet on an optimistic future and I'm definitely keeping an eye on this opportunity with the buy ladders I've mentioned indicated. What's your Bull and Bear case on Moderna? How would you play this in the short and long term?
NASDAQ:MRNA
by Shadowfigure
2
CLX crosses below 100 day EMAClorox NYSE:CLX has really been selling off this month. The stock has dipped below its 100 day exponential moving average more than twice recently. I am going to see if CLX break below the 200 EMA. If so, then the key levels to watch might be that bearish turning point line, which was drawn using previous support levels. Seeing this chart makes me wonder...Is the Coronovirus trade over? As the economy slowly starts to re-open, and talk about the Coronavirus fades into "yesterday's news," can we expect to see a selloff in other stocks that may have benefited from the pandemic? I certainly think so. As the month of November nears, you can expect to hear less about the Coronavirus and more about the upcoming U.S. Presidential election. Hang on to your shorts folks ... its about to get interesting.
NYSE:CLXShort
by UnknownUnicorn6775423
$C6L Swing Trade AnalysisIn this post, I will be going in detail with regards to my view of $C6L from a technical perspective. As of the time that I am writing this post, $C6L is trading at $3.560. I am fully aware that, right now, it may not be the best time to invest in the airline industry due to the uncertainties that surround it. We do not know when a vaccine will be developed, we do not know when a newly developed vaccine will be available for the masses, we do not know whether $C6L will be able to survive the crisis, we do not know whether there will be a new wave of COVID-19 infection, we do not know when international travel will resume, we do not know how long it will take before travelers overcome the fear of getting infected and start traveling in the future. I can write a whole list of reasons why investing in C6L, or any airline company right now is too early. As such, currently, I am bearish on $C6L as long as international traveling is not widely allowed and COVID-19 vaccines are not available for the masses yet. However, despite being aware of all of the above, I still have small positions in $C6L which averaged up to a cost price of $3.652. This is a very long term position that I entered with money that I am comfortable with losing. The reason I did so was that after doing my own due diligence, I strongly believe that $C6L will be able to pull through the COVID-19 crisis because of its strong fundamentals and the financial backing that Singapore provides to the company. Singapore will not let $C6L go under. Of course, this is a very speculative play on my part, so I hope that before you enter into a position into $C6L, think twice, and ensure that you are able to stomach the potential downside that any airline industry investment can bring during such an uncertain period. Technical Analysis I believed that I have broken down the technical aspect of $CCL's chart quite clearly in the candlestick chart above, but just to emphasis on a few things: 1. I strongly believe that if the support zone that I've marked with a star is breached + if everything else remains status quo, or possibly, gets worse, we will definitely revisit $3.200. If the situation remains the same or worse after the retest of $3.200, we will undoubtedly breach it and enter the $3.000 zone and beyond. As such, I believe that right now, we are at a very crucial level from a technical perspective. 2. This is similar to the first point, but I want to emphasize that the upside potential for $C6L is bleak. All, if not most of the movements towards the upside will be extremely dependent on the news releases. Furthermore, even if there are news releases that positively impact $C6L, the upward movement will not be sustainable unless the news is related to confirmation of vaccines being successfully developed and distributed, or if it is regarding a widespread resume of air travel. 3. I believe that currently, should COVID-19 eases and the demand for air travel rises, the fair value of $C6L will be somewhere between $5.500 to $6.000. So, if prices of $C6L push up, my profit target will be right around there. 4. Lastly, I believe that an optimal entry price will be whichever price that $C6L is at when news of vaccines is made available in Singapore (or when there is a news release with a similar impact scale-wise). However, there's also the saying that "Time in the market beats timing the market". As such, you can still enter a small position at the current market price and slowly average down/up; but that is provided that you are able to stomach the possible downside that has still yet to come. Disclaimer I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor. All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment, or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies. I will not and cannot be held liable for any actions you take as a result of anything you read here. Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise. If this post has helped you out in making your investment/trading decision, do it give it a like, and follow for more updates regarding this ticker symbol!
SGX:C6LLong
by UnknownUnicorn6361804
DIS Disney in a Long-Term Correction. What's next?DIS (The Walt Disney Company) is an old favorite for many who have had it or have it in their long-term portfolios, especially with this stock's long-term history. The last 10-20 years have been some of the best for Disney with Bob Iger at the helm and the successful M&A, Creative, Movie launches and much more (Star Wars, MARVEL, New acquisition of FOX properties and much more). The upward momentum for Disney seemed like it would never end. That is, until the pandemic of 2020 proved that Disney was overexposed. Whether theme parks, movie release and launch delays and compromises, and ESPN sports covering nothing interesting for several months, the trifecta took hold and saw DIS take a 50% retracement off its high in just a few weeks. DIS proved resilient. Having already invested in the future of digital with Disney+ and bringing in a new CEO Bob Chapek to lead the new chapter of Disney, there was a glimmer of hope for Disney. Still, long-term market cycles (note my WEEKLY chart) don't recover overnight. Expect DIS to continue seeing volatility in this large consolidation pattern. One might unfortunately link the stock's performance directly to sentiment on the pandemic and any hopes for a vaccine and re-opening of the economy, especially entertainment venues and attractions which Disney is overly dependent on. DIS is a risky stock in the short to mid-term but can be a fun stock to trade while raising money to save a few shares in your long-term investment portfolio.
NYSE:DIS
by Shadowfigure
Potential Long Position GUArea of interest, price has tested the support trend line and rejected it on lower time frames. Price is at an area of confluence due to support and resistance trend lines and 200EMA indicating an area of value. Moreover, it is still bullish according to the 200EMA (Daily). However, fundamental analysis may indicate pound weakness due to Brexit negotiations reaching significant stumbling blocks and NHS workers striking. Furhermore, Dollar may be gaining stregth due to what seems to be a potential second spike emerging globally (France recording highest cases on record and India hitting 100,000 daily infections) indicative of liqudity shifting to the Dollar. Acting as a safe haven. Overall, strong confirmation must be shown before entering a long position on this trade as there is potential for a complete breakout of the current market structure which would offer selling opportunties. Either way, this area of confluence will likely offer good trading positions with a good R:R.
by Tical1
SPX - The second wave has started As we can see on the chart we have broken through the upward channel and we are ready for a correction. The correction on theory should have the TP1 target, but I think there is something else that could be going on. I have the following fundamental reasons for thinking that we will see much deeper drop: - The elections are comming in America and this creates a lot of uncertainty, because of the different policies that could get implemented if whoever gets elected. This makes investors worried and they could pull their invesments out till all of this has cleared. - The second wave of the virus has officialy started already in some countries like South Korea and also in Europe we see huge increase in new confirmed cases. There are many theories about a second wave in September which would be even stronger and this could scare investors aswell and pontetially close lead to closing down businesses which would triger even lower bottom. - The stimulus packages are not going to last forever! They actually helped people through unemployment and also gave a little economy boost, but once it is over, people won't spend money and the economy will slow down again. - There are many tenants who can't pay their rent and the landlords won't be able to recieve that rent, which they need to most likely pay for their mortgage, so this will lead to a chain reaction which will again slow down the economy and most likely cause housing crash. - There are many people who can't repay their loans, because they don't have a job or stable income, so there would be a higher default rate on loans. - The small businesses were damaged heavily by the virus and many of them won't recover, so this will hurt the economy and the people. - The gains we saw in the market are unrealistic and right now everyone is just buying in without good fundamentals, so this is bound to fall sharp at one point or another, because the banks have to take out their profits. When this happens and it is most likely happening right now, the market will fall and wipe out as aways the retail investor. My advice is don't short the economy just yet, rather be well diversified and reduce the risk! Make sure you have some money on the sidelines and be ready to buy into the market if we fall. Aways invest for the long-term and just be ready to buy more. Leave your comments bellow, if you like the idea give it a like!
SP:SPXShort
by donaitelo
4
$ADGS Delivers Award-Winning English E-Learning Tech$ADGS Delivers Award-Winning English E-Learning Curriculum to China and Southeast Asia 09/10/2020 Bringing a true North American academic experience to students throughout the region TORONTO, ON / ACCESSWIRE / September 10, 2020 / ADGS Advisory, Inc (OTC PINK:ADGS) is proud to announce that Quality Online Education Group Inc. (QOEG) has received recognition in China as a winner of online education industry awards in three consecutive years, taking home the prestigious "Most Influential Online Education Service Provider" awards in 2017, 2018, and 2019. The awards are an indicator to QOEG's obvious superiority in being an industry leader in equipping students in China and Southeast Asia with the level of natural English proficiency to be competitive and successful in the global environment of today and tomorrow. English-based academic instruction and North American teaching methods are highly sought after in this region: We have students in nearly every province in China, and we have made an important and successful entry into Vietnam in June 2020. The establishment of this strategic expansion is a significant one, as Vietnam is one of the fastest growing economic centers in Asia. QOEG goes above and beyond expectations in fulfilling the need. Not only is all content development and teaching staff management based in Canada, but the tutors themselves are all highly qualified teachers based in North America and the Philippines. We sincerely believe that this provides a true native English experience, in terms of spoken language fluency, cross-cultural style, and contextual expansion of a child's horizons. As the founder of the QOEG Cambridge Course Development Center, QOEG is an innovative pioneer in bringing the benefits of "small class education" into the online learning environment. Ranging from 1:1 private sessions, to 1:2 or 1:4 "small class" sessions, teaching is done live and online with a North American-based tutor in real-time. Our deepest conviction is that a happy child is an effective learner, and families can easily choose between the different types of sessions, to bring out the best in the student.
ALong
by StockGuild
RVV.C — FDA Phase 3 Clinical Trials Approval for COVID-19 DrugRevive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, July 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. “The FDA approval of the Phase 3 study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 is a tremendous milestone for Revive and I am very proud of the dedication of our team and partners to bring forward a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally,” said Michael Frank, Revive’s Chief Executive Officer. “We thank the FDA for recognizing the importance of this Phase 3 study and we are now focused on executing on our plans for initiating the clinical trial in an expeditious manner.” About the Phase 3 Confirmatory Clinical Study The Phase 3 confirmatory clinical study titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day (“TID”), Bucillamine 200 mg TID or placebo TID for up to 14 days. The primary objective is to compare frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo. The primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death from the time of first dose through Day 28 following randomization. Efficacy will be assessed by comparison of clinical outcome (death or hospitalization), disease severity using the 8-category NIAID COVID ordinal scale, supplemental oxygen use, and progression of COVID‑19 between patients receiving standard-of-care plus Bucillamine (high dose and/or low dose) and patients receiving standard-of-care plus placebo. Safety will be assessed by reported pre-treatment adverse events and treatment-emergent adverse events (including serious adverse events and adverse events of special interest), laboratory values (hematology and serum chemistry), vital signs (heart rate, respiratory rate, and temperature), and peripheral oxygen saturation. An interim analysis will be performed by an Independent Data and Safety Monitoring Board (“DSMB”) after 210 patients have been treated and followed up for a total of 28 days after randomization. The better performing Bucillamine dose at the interim analysis will be selected and patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. Additional interim analyses will be performed after 400, 600, and 800 patients have reached this same post-treatment timepoint. The independent DSMB will actively monitor interim data for the ongoing safety of patients and will recommend continuation, stopping or changes to the conduct of the study based on the interim analysis reports. Scientific Rationale of Bucillamine for COVID-19 Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19. The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
CSE:RVVLong
by wealth_bakery
VST.C -- Gearing up for Wave 2 up move on COVID-19 newsVST has its hand in a number of sectors, including a sizeable holding in FANS (esports/gambling stock) but it has recently gained attention because of its stake in the rapid COVID-19 test manufacturer. Yesterday, they've announced that they are increasing their manufacturing capacity by 5M test kits per month. In the followup webinar, investors were informed of several pending orders with large corporate and government bodies. The company is under NDA at the moment but there will be followup news releases as the orders are fulfilled. Their COVID-19 test has received authorization in a number of major jurisdictions, including most recently Brazil which faces one of the worst COVID-19 outbreaks at the moment. The company reported record numbers in most recent financials, nearly doubling its net income ($4.7M) from the same 6 month period of last year. Technically, yesterday marked a decisive reversal after ~50% retrace from recent high and it appears the chart is gearing up for Wave 2 move that should see re-test (and likely break) through resistance around 1.10. ---------------------------------------------------------------- Victory Square Health Increases Monthly Production of Rapid Covid-19 Test Kits to Meet Increased Demand with New Manufacturing Agreement with Gold Analisa Diagnostica Ltda VANCOUVER, British Columbia, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Victory Square Health Inc./Safetest (“VS Health” or the "Company") – portfolio company of Victory Square Technologies Inc. ("Victory Square") (CSE:VST) (OTC:VSQTF) (FWB:6F6) – is pleased to announce entering into a manufacturing contract for their IgG and IgM Rapid Test Kits for the detection of Covid-19 for sales and distribution globally. The latest manufacturing agreement will allow the company to produce an additional 5,000,000 VS Health Covid-19 Rapid Tests monthly for Global distribution. This additional manufacturing contract will also enable the Company to enter into additional global sales agreements in various industries which have shown interest, including retail, hospitality, pharmaceutical, correctional facilities, casino, border services, education, airport, military, government, and more. “Based on our outreach and discussions, the demand for our exclusive test from distributors around the world is very high,” said Victory Square Health CEO Felipe Peixoto. “Given that demand, this new capacity-building manufacturing contract is a significant boost to our plan to be a positive solution around the world. To that end, Victory Square Health is committed to providing assistance to as many nations as possible through these distribution channels.” The new Victory Square Health/Safetest manufacturer is Gold Analisa Diagnostica Ltda., a Government-recognized manufacturer of bio products in Brazil and has operated for over 30 years. Gold Analisa is ISO 9001: 2015 certified by DNV - DET NORSKE VERITAS in the scope of production, marketing and technical-scientific advisory services for products for in vitro diagnostic use. Gold Analisa has Anvisa's Good Manufacturing and Control Practices certificate with hivital, and also participates in the PNCQ - National Quality Control Program, sponsored by SBAC – Sociedade Brasileira de Análises Clínicas. Gold Analisa has a distribution network that aims to be close to customers, covering the entire national territory of Brazil. “We’re completely energized by this critical new manufacturing contract which will allow Victory Square Health to fulfill the tremendous demand for its exclusive Rapid Test kits on a global scale,” said Shafin Diamond Tejani, CEO of Victory Square Technologies, of which Victory Square Health is a portfolio company. “We are actively working together on other production partnership agreements to further increase our production capacity.”
CSE:VSTLong
by wealth_bakery
ETH - Bear before Stimulus CheckThis is not a financial advice. According to news, the next stimulus check is going to be given in the near future (for US). That is going to bring more investment in Gold, Silver and Crypto. (if you are interested in Gold, check my monthly Gold chart in Related ideas below this) Before the time we see the next stimulus check, we probably see another correction. The midterm target for Ethereum is $1,400. (this is based on my calculations, so research on your own before exercising any trade)
Short
by PersianAnger
1